Trial reportAmerican journal of hypertension2017
Metoprolol Increases Uric Acid and Risk of Gout in African Americans With Chronic Kidney Disease Attributed to Hypertension.
Trial report in American journal of hypertension, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00582777 (African American Study of Kidney Disease and Hypertension ABPM Pilot Study), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
African American Study of Kidney Disease and Hypertension ABPM Pilot Study
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Effects of the DASH diet and losartan on serum urate among adults with hypertension: Results of a randomized trial.Journal of clinical hypertension (Greenwich, Conn.) · 2023Trial
- Effects of a Dietary Approach to Stop Hypertension (DASH) Diet Intervention on Serum Uric Acid in African Americans With Hypertension.Arthritis care & research · 2018Trial
- Pharmacovigilance assessment of gout: a real-world study using the FAERS database.Frontiers in pharmacology · 2026Article
- Review
- [Diagnostics and treatment of gout : Short version of the German S3 guideline].Zeitschrift fur Rheumatologie · 2025Review
- The Impact of Hyperuricemia on Pharmacokinetics in Sprague-Dawley Rats.European journal of drug metabolism and pharmacokinetics · 2025Article
- A Retrospective Cross-Sectional Study on the Clinicopathologic Features of Essential Hypertension at High Altitude in China.Cardiovascular therapeutics · 2025Article
- Current perspectives and trends of the research on hypertensive nephropathy: a bibliometric analysis from 2000 to 2023.Renal failure · 2024Review
- The Efficacy and Safety of Dotinurad on Uric Acid and Renal Function in Patients with Hyperuricemia and Advanced Chronic Kidney Disease: A Single Center, Retrospective Analysis.Drug design, development and therapy · 2023Article
- Environmental Triggers of Hyperuricemia and Gout.Rheumatic diseases clinics of North America · 2022Review
- Lowering and Raising Serum Urate Levels: Off-Label Effects of Commonly Used Medications.Mayo Clinic proceedings · 2022Review
- Prevalence of Hyperuricemia and Associated Factors Among Type 2 Diabetic Patients in Jordan.International journal of general medicine · 2022Article
- Risk factors and management of hyperuricemia after renal transplantation.Frontiers in surgery · 2022Review
- Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update.Medicina (Kaunas, Lithuania) · 2021Review
- Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2021Review
- Survey on uric acid in Chinese subjects with essential hypertension (SUCCESS): a nationwide cross-sectional study.Annals of translational medicine · 2021Article
- The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.Journal of hypertension · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThere is little evidence guiding selection of nondiuretic, antihypertensive agents with a goal of lowering uric acid (SUA) and minimizing gout risk.
methodsIn the African American Study of Kidney Disease and Hypertension (AASK) trial, African Americans with chronic kidney disease were randomly assigned to metoprolol (a beta-blocker), ramipril (an angiotensin-converting enzyme inhibitors [ACEi]), or amlodipine (a dihydropyridine calcium-channel blocker). SUA was measured at baseline and 12 months. Gout-related hospitalizations were based on ICD9 codes. Gout-related medication use (GRMs) was based on active prescriptions of allopurinol, colchicine, or probenecid during the baseline visit of the AASK cohort phase. We examined the effect of drug assignment on 12-month SUA (linear regression), gout-related hospitalization (Cox regression), and GRM (logistic regression).
resultsOf the 630 participants, 40% were female with a mean age of 55 years (SD, 10), mean SUA of 8.2 mg/dl (2.0), and mean serum creatinine of 1.8 mg/dl (0.6). After 12 months, metoprolol increased SUA by 0.3 mg/dl, while ramipril or amlodipine had no effect on SUA. Compared to ramipril, metoprolol significantly increased 12-month SUA (0.40; 0.10, 0.70 mg/dl; P = 0.009), nonsignificantly increased risk of gout-related hospitalization (hazard ratio: 3.87; 0.82, 18.26; P = 0.09), and significantly increased the odds of GRM (odds ratio: 1.62; 1.03, 2.54; P = 0.04). While metoprolol was associated with a higher 12-month SUA compared with amlodipine (0.57; 0.18, 0.95; P = 0.004), there was no difference in gout-related hospitalizations or GRM.
conclusionsMetoprolol increased SUA and GRM in African American adults. Health professionals treating patients with kidney disease at risk for gout should avoid metoprolol and possibly consider an ACEi. CLINICAL TRIALS REGISTRATION: Trial Number NCT00582777.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.